Congress bets $billions on generic drug factories—with no price guarantee
S. 1891 — PILLS Act · Filed by Tom Cotton (R-AR) · Introduced May 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The PILLS Act creates two federal tax credits to incentivize domestic production of generic drugs and biosimilars: a 30–35% production credit on the value added by manufacturers (rising to 40% with domestic-content bonuses), and a 25% investment credit for capital equipment and facilities. Both credits phase out after 2030 and 2028 respectively, exclude foreign entities of concern, and allow companies to elect direct government payment instead of claiming credits on tax returns.
Why we flagged it
The bill's operative mechanism is a direct tax credit and investment subsidy flowing to private generic drug and biosimilar manufacturers. While framed as supply-chain resilience, it functions as a targeted industry tax break with no price-control or consumer-benefit mandate.
What the text implies
- Credits are available to any manufacturer meeting eligibility criteria, but the 25% investment credit terminates after Dec. 31, 2028, creating a cliff that may discourage long-term facility investment after that date.
- The 'foreign entity of concern' exclusion (referencing the 2021 NDAA definition) may be narrower than intended if that definition is later narrowed or repealed, potentially allowing excluded entities back in.
The full analysis lists 5 implications of this text.
Who stands to gain
generic drug manufacturers; biosimilar manufacturers; pharmaceutical contract manufacturers